Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16531
Title: | Drug-specific upregulation of CD137 on CD8+ T cells aids in the diagnosis of multiple antibiotic toxic epidermal necrolysis | Austin Authors: | Trubiano, Jason ;Redwood, Alec;Strautins, Kaija;Pavlos, Rebecca;Woolnough, Emily;Chang, Christina C;Phillips, Elizabeth | Affiliation: | Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia Department of Infectious Diseases, Alfred Health, Melbourne, Victoria, Australia Department of Medicine, University of Melbourne, Parkville, Victoria, Australia Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA Department of Pharmacology, Oates Institute for Experimental Therapeutics, Vanderbilt University Medical School, Nashville, Tennessee, USA |
Issue Date: | May-2017 | Date: | 2016-11-22 | Publication information: | The Journal of Allergy and Clinical Immunology: In Practice 2017; 5(3): 823-826 | Abstract: | There are major challenges defining drug causality in cases of severe cutaneous adverse reactions (SCAR) involving multiple antibiotics. We describe a case of toxic epidermal necrolysis (TEN) occurring in the setting of multiple antibiotics and the use of IFN-γ enzyme-linked immunospot assay and flow cytometry to clarify causality. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/16531 | DOI: | 10.1016/j.jaip.2016.09.043 | ORCID: | 0000-0002-5111-6367 | Journal: | The Journal of Allergy and Clinical Immunology: In Practice | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/27888029 | Type: | Journal Article | Type of Clinical Study or Trial: | Case Series and Case Reports |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.